# A Study of IBI306 in Participants With Hypercholesterolemia

> **NCT04709536** · PHASE3 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 306 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** IBI306
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04709536
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-09
- **Primary completion:** 2021-11-09
- **Final completion:** 2022-01-28
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04709536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04709536, "A Study of IBI306 in Participants With Hypercholesterolemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04709536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*